Effect of Immune System on Retrovirus-Mediated Herpes Simplex Virus Thymidine Kinase Gene Therapy.
10.4046/trd.1999.46.2.229
- Author:
Jae Yong PARK
;
Soyoung JOO
;
Hee Jin CHANG
;
Ji Woong SON
;
Kwan Young KIM
;
Keong Seok KIM
;
Chang Ho KIM
;
Jae Ho PARK
;
Jong Ki LEE
;
Tae Hoon JUNG
- Publication Type:In Vitro ; Original Article ; Clinical Trial
- Keywords:
Immunity;
Retrovirus;
HSV-Thymidine Kinase;
Gene Therapy
- MeSH:
Animals;
Antibodies, Neutralizing;
Antigens, Neoplasm;
Cyclosporine;
Cytokines;
Ganciclovir;
Genes, Neoplasm;
Genetic Therapy*;
Hand;
Herpes Simplex*;
Immune System*;
Immunity, Cellular;
Immunosuppression;
Mesothelioma;
Mice;
Mice, SCID;
Models, Animal;
Phosphotransferases*;
Retroviridae;
Simplexvirus*;
T-Lymphocytes, Cytotoxic;
Thymidine Kinase;
Transgenes;
Tumor Burden;
Viral Proteins;
Zidovudine
- From:Tuberculosis and Respiratory Diseases
1999;46(2):229-240
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The impact of the immune response on cancer gene therapy using viral vectors to deliver a "suicide gene" is currently unclear. A vigrous immune response targeted at viral proteins or transgene may enhance the efficacy of tumor destruction and even augment responses to tumor antigens. These responses may involve the release of cytokines and stimulation of tumor specific cytotoxic T-lymphocytes that enhance therapeutic efficacy. On the other hand, a vigorous rapid cellular immune response may destroy cells expressing the therapeutic gene and attenuate the response to therapy. Furthermore, development of neutralizing antibody responses may prevent readministration of virus, a potentially significant limitation. Evaluating the significance of these limitations in animal models and developing solutions are therefore of obvious importance. METHODS: After retroviral transduction of mouse mesothelioma cell line(AB12) with Herpes Simplex Virus thymidine kinase (HSVtk) gene in vitro, subcutaneous flank tumors were established. To study the effect of intact immune system on efficacy of tumor erradication, the ability of the HSVtk/ganciclovir system to inhibit tumor growth was compared among normal Balb/c mice, immunodeficient Balb/c-nude and SCID mice, and Balb/c mice immunosuppressed with cyclosporin. RESULTS: Ganciclovir treatment resulted in greater inhibition of tumor growth in Balb/c mice compared with immunodeficient Balb/c-nude mice and SCID mice(in immunodeficient mice, there were no growth inhibition by ganciclovir treatment). Ganciclovir treatment resulted in greater inhibition of tumor growth in non-cyclosporin (CSA) treated Balb/c mice compared with CSA treated Balb/c mice. On day 8, mean ganciclovir-treated tumor volume were 65% of control tumor volume in Balb/c mice versus 77% control tumor volume in CSA-treated Balb/c mice. This effect was still evident during therapy (day 11 and 13). On day 13, non-CSA treated tumor volume was 35% of control tumor volume versus 60% of control tumor volume in CSA treated Balb/c mice. Duration of expression of HSVtk was not affected by the immunosuppression with CSA. CONCLUSION: These results indicate that the immune responses against retrovirally transduced cells enhance the efficacy of the HSVtk/ganciclovir system. These findings have important implications for clinical trials using currently available retrovirus vectors as well as for future vector design.
